16:00 EDT AnaptysBio (ANAB) trading halted, news pending
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio jumps after Englander’s Millennium takes stake
- AnaptysBio’s Promising Potential in Ulcerative Colitis Market Drives Buy Rating
- AnaptysBio falls after data abstract on Lilly’s peresolimab
- Reaction to peresolimab update ‘seems excessive,’ says TD Cowen
- AnaptysBio price target raised to $20 from $18 at UBS